Icahn funds unload stakes in Biogen, Amgen

A few drugmakers might breathe sighs of relief at activist investor Carl Icahn's (photo) latest portfolio update. Icahn's investment vehicles appear to have sold out of Biogen Idec, at which they forced two proxy fights, as well as Amgen and Regeneron Pharmaceuticals. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.